News

Catch up on the clinical trial news, updates from the United States Food and Drug Administration (FDA), and company funding that you may have missed.

These resources include downloadable fact sheets, glaucoma financial assistance resources, shareable social media graphics, and a dedicated webpage.

The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to abnormal in any electrocardiogram (ECG).

Investigators reported that the trial demonstrated significant improvements in visual function and retinal structure for patients with optic neuritis

The collaboration between KIST and Huons BioPharma will span 14 months.

The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to abnormal in any electrocardiogram (ECG).

Patients with fibromyalgia experienced changes in the macular ganglion cell layer and retinal nerve fiber layer.

Most recently, Jacques served as Vice President of Healthcare Strategy, Partnerships & M&A at Microsoft.

The multinational, multicenter, prospective RESTORE Study is the 5-year follow-up study of the phase 3 clinical RESCUE and REVERSE Studies of lenadogene nolparvovec to treat vision loss from LHON due to the MT-ND4 mutation.

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition

LHON, a genetic disease that affects the retinal ganglion cells, results in severe bilateral sequential vision loss.

The RESTORE Study is the follow-up study of the RESCUE and REVERSE studies of lenadogene nolparvovec to treat vision loss from LHON

The potential gene therapy candidate is being evaluated for geographic atrophy.

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition.

Lana Rifkin, MD, a uveitis specialist at Ophthalmic Consultants of Boston, shared insights into her work and her role as committee chair of the uveitis section for the upcoming EnVision Summit, which will be held from February 14 to 17, 2025, at the Caribe Hilton San Juan in Puerto Rico.

The rationale was that commercial mydriatics administered during retinopathy of prematurity (ROP) screening have been associated with cardiorespiratory and gastrointestinal adverse events.

The rationale was that commercial mydriatics administered during retinopathy of prematurity (ROP) screening have been associated with cardiorespiratory and gastrointestinal adverse events.

A study conducted with over 77,000 individuals found that alcohol consumption increased the risk of dry eye in women.

The trial is evaluating GAL-101 eye drops in patients with geographic atrophy, an advanced form of dry AMD.

Investigators emphasised the need for continued efforts to raise awareness and support patients in attending regular screening

In this study, researchers examine immune mechanisms in ocular diseases like uveitis, AMD, DR, and GO, highlighting microglial roles, targeted therapies, and promising advances in immunotherapy.

This year was brimming with advancements in eye care.

Enhanced monofocal IOLs provide a slight depth-of-focus boost without compromising contrast, making them a versatile choice for patients seeking improved distance and intermediate vision while still needing glasses for near tasks.

According to Robert Latkany, MD, understanding the causes and recognizing these diagnostic features are essential for effective treatment.

Hot topics around the globe, from clinical trials to the solar eclipse

Trending topics and milestone stories from our year in ophthalmology.